A provider briefing on the Blisovi 24 Fe 1/20 shortage in 2026. Coverage of supply timeline, prescribing implications, alternatives, and tools for your practice.
If your patients on Blisovi 24 Fe 1/20 (norethindrone acetate 1 mg / ethinyl estradiol 20 mcg, 24/4 regimen) have been reporting difficulty filling prescriptions, you're hearing a real and ongoing problem. This briefing covers the current supply landscape, prescribing implications, and practical tools to help your practice manage through the disruption.
Oral contraceptive supply chain issues are not new, but they've intensified over the past several years:
The intermittent nature of the shortage creates several clinical considerations:
Patients who cannot fill their prescription on time face gaps in contraceptive coverage. Even short interruptions (2-3 missed days) can trigger ovulation, particularly with low-dose formulations like this 20 mcg ethinyl estradiol product. Counsel patients to use backup contraception if any gap occurs and to contact your office promptly rather than simply waiting for stock to return.
Pharmacy-level substitutions to AB-rated equivalents (Junel Fe 24, Hailey 24 Fe, Aurovela 24 Fe) are generally seamless from a clinical standpoint — same active ingredients, same doses, same regimen. However, patients may not understand this and may be anxious about a "new" medication. Proactive counseling that these are identical products from different manufacturers can reduce non-adherence due to confusion.
If all 24/4 norethindrone acetate/ethinyl estradiol generics are unavailable, switching to a different formulation requires clinical judgment. Consider:
For patients with drug interaction considerations, verify that the alternative doesn't introduce new interaction risks.
Availability varies significantly by geography, pharmacy type, and wholesaler relationships:
Medfinder for Providers offers real-time pharmacy stock data that your staff can use to direct patients to pharmacies with current availability, reducing call volume and patient frustration.
Blisovi 24 Fe 1/20 is a Tier 1 generic on most formularies:
For patients switching to Lo Loestrin Fe due to availability, be aware of the significant cost increase. Prior authorization may be required, and some plans may require step therapy documentation showing generic alternatives were tried first.
Medfinder provides real-time pharmacy inventory data. Your front desk or nursing staff can search for Blisovi 24 Fe 1/20 availability by zip code and direct patients to pharmacies that have stock. This is especially useful for same-day prescription needs.
Consider sharing these resources with affected patients:
The oral contraceptive supply chain is gradually improving as manufacturers invest in additional capacity. However, full stabilization is unlikely in the near term. The limited number of API suppliers and the concentrated manufacturing base for hormonal contraceptives mean that disruptions will likely continue to create periodic availability gaps.
Practices that build flexibility into their prescribing — allowing substitution, writing by generic name, and using tools like Medfinder — will be best positioned to minimize the impact on patient care.
The Blisovi 24 Fe 1/20 shortage is a supply chain problem, not a clinical one. The medication remains effective and appropriate for its approved indications. The challenge is getting it into patients' hands consistently. By leveraging real-time availability tools, writing flexible prescriptions, and proactively educating patients about equivalent alternatives, providers can significantly reduce the burden of this ongoing disruption.
For more provider resources, visit medfinder.com/providers.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
